Ganirelix
GnRH antagonist for IVF ovarian stimulation protocols. Prevents premature LH surge during controlled ovarian hyperstimulation, optimizing oocyte retrieval outcomes in assisted reproduction.
Ganirelix Acetate is a third-generation GnRH antagonist and a synthetic decapeptide used in assisted reproductive technology (ART) to prevent premature LH surge during controlled ovarian stimulation (COS). It competitively blocks GnRH receptors, rapidly suppressing LH and FSH release for precise ovulation timing control.
| Parameter | Specification |
| CAS | 123246-29-7 |
| Molecular Formula | C₈₀H₁₁₃ClN₁₈O₁₃ |
| Molecular Weight | 1570.34 g/mol |
| Category | GnRH/Reproductive |
| Purity | ≥99% |
| Status | GMP-compliant, FDA-ready |
| Applications | IVF ovarian stimulation, fertility treatment, LH surge prevention |
| CAS | 123246-29-7 |
|---|---|
| Applications | Controlled Ovarian Hyperstimulation, Infertility Treatment, IVF Ovarian Stimulation |
Related products
-
Teduglutide
CAS: 197922-42-2Applications: Crohn Disease, GLP-2, Intestinal Repair, Short Bowel Syndrome -
Liraglutide
CAS: 204656-20-2Applications: cardiovascular risk reduction, GLP-1, obesity management -
Aviptadil
CAS: 40077-57-4Applications: Acute respiratory distress syndrome, ARDS, Lung protection, Pulmonary hypertension, VIP analog -
Mazdutide
CAS: 2259884-03-0Applications: metabolic syndrome, Overweight treatment, Type 2 diabetes